中国特应性皮炎的研究现状与展望

doi:10.35541/cjd.20260077

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (6): 505-511.doi: 10.35541/cjd.20260077

• 专家论坛·特应性皮炎 • 上一篇下一篇

中国特应性皮炎的研究现状与展望

李巍¹,姚煦²

¹复旦大学附属华山医院皮肤科，上海 200040；²中国医学科学院北京协和医学院，皮肤病医院过敏与风湿免疫科，南京 210042

收稿日期:2026-02-05 修回日期:2026-04-12 发布日期:2026-06-05
通讯作者: 李巍；姚煦 E-mail:liweiderma@fudan.edu.cn; dryao_xu@126.com
基金资助:
国家自然科学基金（82330098，82530099）

Research on atopic dermatitis in China: current status and future perspectives

Li Wei¹, Yao Xu²

¹Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China; ²Department of Allergy and Rheumatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Nanjing 210042, China

Received:2026-02-05 Revised:2026-04-12 Published:2026-06-05
Contact: Li Wei; Yao Xu E-mail:liweiderma@fudan.edu.cn; dryao_xu@126.com
Supported by:
National Natural Science Foundation of China（82330098，82530099）

摘要/Abstract

摘要： 【摘要】特应性皮炎（AD）是一种复杂的炎症性皮肤病。近20年来，我国AD患病率持续增长。因临床表现常呈现不典型特征，已有多种诊断标准被提出和验证。遗传学研究显示，中国AD患者既存在与高加索人群一致的易感基因位点，也存在独特的遗传位点。在发病机制上，皮肤微生物组在AD的发病中起重要作用，皮肤中的免疫细胞则是AD发病机制中的关键效应细胞，神经免疫机制也参与了AD炎症应答的发生发展。近年来，以生物制剂和Janus激酶抑制剂为代表的新型系统治疗药物在我国AD患者中展现出良好的疗效与安全性。我国学者在AD领域的研究推动了对该病的认识和疾病管理。

关键词: 皮炎, 特应性, 内型, 诊断, 发病机制, 微生物组, 炎症, 生物制剂, Janus激酶抑制剂

Abstract: 【Abstract】 Atopic dermatitis （AD） is a complex inflammatory skin disorder. Over the past two decades, the prevalence of AD in China has been continuously increasing. Due to the atypical clinical manifestations of AD commonly seen in Chinese patients, several diagnostic criteria have been proposed and validated. Genetic studies have revealed that Chinese patients with AD share some susceptible loci with Caucasian populations, and also harbor unique susceptible loci. Regarding pathogenesis, the skin microbiome plays an important role in the development of AD. Meanwhile, immune cells in the skin serve as key effector cells that orchestrate various functions in AD. Neuroimmune mechanisms are also involved in the initiation and progression of inflammatory responses in AD. In recent years, novel systemic treatments, represented by biologics and Janus kinase inhibitors, have demonstrated favorable efficacy and safety profiles in Chinese AD patients. Collectively, research advances in the pathogenesis and treatment of AD made by Chinese scholars have significantly improved the understanding and management of AD.

Key words: Dermatitis, atopic, Endotype, Diagnosis, Pathogenesis, Microbiome, Inflammation, Biologics, Janus kinase inhibitor

李巍姚煦. 中国特应性皮炎的研究现状与展望[J]. 中华皮肤科杂志, 2026,59(6):505-511. doi:10.35541/cjd.20260077

Li Wei¹, Yao Xu². Research on atopic dermatitis in China: current status and future perspectives[J]. Chinese Journal of Dermatology, 2026, 59(6): 505-511.doi:10.35541/cjd.20260077

参考文献 77

［1］	Gu C, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China［J］. J Clin Med, 2023,12（16）:5370. DOI: 10.3390/jcm12165370.
［2］	康克非, 田润梅. 遗传过敏性皮炎诊断标准的探讨［J］. 临床皮肤科杂志, 1986,15（2）:60⁃63.
［3］	顾恒, 颜艳, 陈崑, 等. 我国特应性皮炎流行病学调查［J］. 中华皮肤科杂志, 2000,33（6）:379⁃382.
［4］	顾恒, 尤立平, 刘永生, 等. 我国10城市学龄前儿童特应性皮炎现况调查［J］. 中华皮肤科杂志, 2004,37（1）:29⁃31.
［5］	Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis［J］. Chin Med J （Engl）, 2016,129（7）:757⁃762. DOI: 10.4103/0366⁃6999.178960.
［6］	Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1⁃12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence［J］. J Eur Acad Dermatol Venereol, 2019,33（8）:1569⁃1576. DOI: 10.1111/jdv.15618.
［7］	Xu F, Yan S, Li F, et al. Prevalence of childhood atopic dermatitis: an urban and rural community⁃based study in Shanghai, China［J］. PLoS One, 2012,7（5）:e36174. DOI: 10. 1371/journal.pone.0036174.
［8］	Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1 - 7 ys［J］. Sci Rep, 2016,6:29751. DOI: 10.1038/srep29751.
［9］	Mao D, Li J, Liu S, et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population⁃based cross⁃sectional study［J］. Chin Med J （Engl）, 2023,136（5）:604⁃606. DOI: 10.1097/CM9.0000000000002560.
［10］	Xu F, Yan S, Zheng Q, et al. Residential risk factors for atopic dermatitis in 3⁃ to 6⁃year old children: a cross⁃sectional study in Shanghai, China［J］. Int J Environ Res Public Health, 2016,13（6）:537. DOI: 10.3390/ijerph13060537.
［11］	Li Q, Yang Y, Chen R, et al. Ambient air pollution, meteorological factors and outpatient visits for eczema in Shanghai, China: a time⁃series analysis［J］. Int J Environ Res Public Health, 2016,13（11）:1106. DOI: 10.3390/ijerph13111106.
［12］	Ege MJ. The hygiene hypothesis in the age of the microbiome［J］. Ann Am Thorac Soc, 2017,14（Supplement_5）:S348⁃S353. DOI: 10.1513/AnnalsATS.201702⁃139AW.
［13］	Yang Z, Chen Z, Lin X, et al. Rural environment reduces allergic inflammation by modulating the gut microbiota［J］. Gut Microbes, 2022,14（1）:2125733. DOI: 10.1080/19490976.2022.2125733.
［14］	Liu X, Xu J, Wang Z, et al. Differential changes in the gut microbiota between extrinsic and intrinsic atopic dermatitis［J］. J Autoimmun, 2023,141:103096. DOI: 10.1016/j.jaut.2023.103096.
［15］	Liu X, Xu B, Xu X, et al. Attenuation of allergen⁃specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine［J］. Cell Rep Med, 2023,4（12）:101340. DOI: 10.1016/j.xcrm.2023.101340.
［16］	Shi M, Zhang H, Chen X, et al. Clinical features of atopic dermatitis in a hospital⁃based setting in China ［J］. J Eur Acad Dermatol Venereol, 2011,25（10）:1206⁃1212. DOI: 10.1111/j. 1468⁃3083.2010.03933.x.
［17］	Li Z, Yin H, Wang Y, et al. Temporal and topographical heterogeneities in clinical manifestations of atopic dermatitis in China［J］. J Clin Med, 2025,14（3）:840. DOI: 10.3390/jcm140 30840.
［18］	Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China［J］. J Eur Acad Dermatol Venereol, 2020, 34（10）:2346⁃2352. DOI: 10. 1111/jdv.16346.
［19］	Luo Y, Fang X, Zhou Y, et al. Senescent fibroblasts and innate immune cell activation might play a role in the pathogenesis of elderly atopic dermatitis［J］. J Dermatol Sci, 2024,114（3）:94⁃103. DOI: 10.1016/j.jdermsci.2024.04.002.
［20］	Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:542⁃548. DOI: 10.1111/jdv.15979.
［21］	Yue W, Cheng D, Sun Z, et al. Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting⁃based study［J］. Br J Dermatol, 2023,188（3）:420⁃426. DOI: 10.1093/bjd/ljac097.
［22］	Wang S; Li Z; Gu C, et al. Development and validation of diagnostic criteria for elderly atopic dermatitis［J］. Int J Dermatol Venereol, 2024, 7（1）:1⁃5. DOI: 10.1097/JD9.0000000000000349.
［23］	Sun LD, Xiao FL, Li Y, et al. Genome⁃wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population［J］. Nat Genet, 2011,43（7）:690⁃694. DOI: 10.1038/ng.851.
［24］	Wu YY, Tang JP, Liu Q, et al. Scanning indels in the 5q22.1 region and identification of the TMEM232 susceptibility gene that is associated with atopic dermatitis in the Chinese Han population［J］. Gene, 2017,617:17⁃23. DOI: 10.1016/j.gene. 2017.03.034.
［25］	Zheng J, Wu YY, Fang WL, et al. Confirming the TMEM232 gene associated with atopic dermatitis through targeted capture sequencing［J］. Sci Rep, 2021,11（1）:21830. DOI: 10.1038/s41598⁃021⁃01194⁃6.
［26］	Han J, Cai X, Qin S, et al. TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor⁃κB and signal transducer and activator of transcription 3 signalling pathways［J］. Br J Dermatol, 2023,189（2）:195⁃209. DOI: 10. 1093/bjd/ljad078.
［27］	Cai XY, Cheng L, Yu CX, et al. GWAS follow⁃up study discovers a novel genetic signal on 10q21.2 for atopic dermatitis in Chinese Han population［J］. Front Genet, 2019,10:174. DOI: 10.3389/fgene.2019.00174.
［28］	Shen C, Liu L, Jiang Z, et al. Four genetic variants interact to confer susceptibility to atopic dermatitis in Chinese Han population［J］. Mol Genet Genomics, 2015,290（4）:1493⁃1498. DOI: 10.1007/s00438⁃015⁃1014⁃x.
［29］	Zhang H, Guo Y, Wang W, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis［J］. Allergy, 2011,66（3）:420⁃427. DOI: 10.1111/j.1398⁃9995.2010.02493.x.
［30］	Cheng R, Li M, Zhang H, et al. Common FLG mutation K4671X not associated with atopic dermatitis in Han Chinese in a family association study［J］. PLoS One, 2012,7（11）:e49158. DOI: 10. 1371/journal.pone.0049158.
［31］	Li M, Liu JB, Liu Q, et al. Interactions between FLG mutations and allergens in atopic dermatitis［J］. Arch Dermatol Res, 2012,304（10）:787⁃793. DOI: 10.1007/s00403⁃012⁃1282⁃9.
［32］	Zhang Z, Li H, Zhang H, et al. Factors associated with persistence of early⁃onset atopic dermatitis up to the age of 12 years: a prospective cohort study in China［J］. Eur J Dermatol, 2021,31（3）:403⁃408. DOI: 10.1684/ejd.2021.4045.
［33］	Liang Y, Wang P, Zhao M, et al. Demethylation of the FCER1G promoter leads to FcεRI overexpression on monocytes of patients with atopic dermatitis［J］. Allergy, 2012,67（3）:424⁃430. DOI: 10.1111/j.1398⁃9995.2011.02760.x.
［34］	Liang Y, Yu B, Chen J, et al. Thymic stromal lymphopoietin epigenetically upregulates Fc receptor γ subunit⁃related receptors on antigen⁃presenting cells and induces TH2/TH17 polarization through dectin⁃2［J］. J Allergy Clin Immunol, 2019,144（4）:1025⁃1035. DOI: 10.1016/j.jaci.2019.06.011.
［35］	Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis［J］. Genome Res, 2012,22（5）:850⁃859. DOI: 10.1101/gr.131029.111.
［36］	Chng KR, Tay AS, Li C, et al. Whole metagenome profiling reveals skin microbiome⁃dependent susceptibility to atopic dermatitis flare［J］. Nat Microbiol, 2016,1（9）:16106. DOI: 10. 1038/nmicrobiol.2016.106.
［37］	Li W, Xu X, Wen H, et al. Inverse association between the skin and oral microbiota in atopic dermatitis［J］. J Invest Dermatol, 2019,139（8）:1779⁃1787. DOI: 10.1016/j.jid.2019.02.009.
［38］	Liu Y, Wang S, Dai W, et al. Distinct skin microbiota imbalance and responses to clinical treatment in children with atopic dermatitis［J］. Front Cell Infect Microbiol, 2020,10:336. DOI: 10.3389/fcimb.2020.00336.
［39］	Yu J, Luo Y, Zhu Z, et al. A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor［J］. J Allergy Clin Immunol, 2019,143（6）:2108⁃2119. DOI: 10.1016/j.jaci. 2018.11.036.
［40］	Liu X, Zhang X, Zhang J, et al. Activation of aryl hydrocarbon receptor in Langerhans cells by a microbial metabolite of tryptophan negatively regulates skin inflammation［J］. J Dermatol Sci, 2020,100（3）:192⁃200. DOI: 10.1016/j.jdermsci.2020.10. 004.
［41］	Qiu Z, Zhu Z, Liu X, et al. A dysregulated sebum⁃microbial metabolite⁃IL⁃33 axis initiates skin inflammation in atopic dermatitis［J］. J Exp Med, 2022,219（10）:e20212397. DOI: 10.1084/jem.20212397.
［42］	Byrd AL, Belkaid Y, Segre JA. The human skin microbiome［J］. Nat Rev Microbiol, 2018,16（3）:143⁃155. DOI: 10.1038/nrmicro. 2017.157.
［43］	Lee YB, Byun EJ, Kim HS. Potential role of the microbiome in acne: a comprehensive review［J］. J Clin Med, 2019,8（7）:987. DOI: 10.3390/jcm8070987.
［44］	Yu T, Xu X, Liu Y, et al. Multi⁃omics signatures reveal genomic and functional heterogeneity of Cutibacterium acnes in normal and diseased skin［J］. Cell Host Microbe, 2024,32（7）:1129⁃1146. DOI: 10.1016/j.chom.2024.06.002.
［45］	Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function［J］. Nat Rev Immunol, 2019,19（2）:89⁃103. DOI: 10.1038/s41577⁃018⁃0088⁃1.
［46］	Zhu R, Yao X, Li W. Langerhans cells and skin immune diseases［J］. Eur J Immunol, 2024,54（10）:e2250280. DOI: 10.1002/eji.202250280.
［47］	Zhang Y, Luo Y, Li W, et al. DC⁃SIGN promotes allergen uptake and activation of dendritic cells in patients with atopic dermatitis［J］. J Dermatol Sci, 2016,84（2）:128⁃136. DOI: 10.1016/j.jdermsci.2016.08.008.
［48］	Luo X, Chen J, Yang H, et al. Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKⅡ⁃involved mast cell activation［J］. JCI Insight, 2022,7（5）:e152559. DOI: 10.1172/jci.insight.152559.
［49］	Gao C, Zhao Y, Ge L, et al. Distinct maturation, glucose metabolism, and inflammatory function of human monocytes⁃derived IDECs mediated by anti⁃IgE and Pam3CSK4 alone or in combination［J］. Front Immunol, 2024,15:1403263. DOI: 10.3389/ fimmu.2024.1403263.
［50］	Li W, Zhang Z, Saxon A, et al. Prevention of oral food allergy sensitization via skin application of food allergen in a mouse model［J］. Allergy, 2012,67（5）:622⁃629. DOI: 10.1111/j.1398⁃9995.2012.02798.x.
［51］	Luo Y, Wang S, Liu X, et al. Langerhans cells mediate the skin⁃induced tolerance to ovalbumin via Langerin in a murine model［J］. Allergy, 2019,74（9）:1738⁃1747. DOI: 10.1111/all.13813.
［52］	Liu X, Zhu R, Luo Y, et al. Distinct human Langerhans cell subsets orchestrate reciprocal functions and require different developmental regulation［J］. Immunity, 2021,54（10）:2305⁃2320. DOI: 10.1016/j.immuni.2021.08.012.
［53］	Li W, Yosipovitch G. The role of the microbiome and microbiome⁃derived metabolites in atopic dermatitis and non⁃histaminergic itch［J］. Am J Clin Dermatol, 2020,21（Suppl 1）:44⁃50. DOI: 10.1007/s40257⁃020⁃00538⁃8.
［54］	Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:239⁃250. DOI: 10.1111/jdv.15973.
［55］	Wang F, Trier AM, Li F, et al. A basophil⁃neuronal axis promotes itch［J］. Cell, 2021,184（2）:422⁃440. DOI: 10.1016/j.cell.2020.12.033.
［56］	Li H, Li C, Zhang H, et al. Effects of lidocaine on regulatory T cells in atopic dermatitis［J］. J Allergy Clin Immunol, 2016,137（2）:613⁃617. DOI: 10.1016/j.jaci.2015.07.039.
［57］	Sun PY, Li HG, Xu QY, et al. Lidocaine alleviates inflammation and pruritus in atopic dermatitis by blocking different population of sensory neurons［J］. Br J Pharmacol, 2023,180（10）:1339⁃1361. DOI: 10.1111/bph.16012.
［58］	Xu Y, Qiu Z, Gu C, et al. Propionate alleviates itch in murine models of atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion［J］. Allergy, 2024,79（5）:1271⁃1290. DOI: 10.1111/all.15998.
［59］	Yu S, Xu Y, Li Y, et al. Sympathetic nerve dysfunction exacerbates skin inflammation in atopic dermatitis［J］. J Allergy Clin Immunol, 2026,157（3）:677⁃692. DOI: 10.1016/j.jaci.2025. 12.994.
［60］	Xie X, Jiang W, Lun L, et al. Hyperactivation of sympathetic nerves fuels basophil infiltration in atopic dermatitis［J］. Immunity, 2026,59（3）:598⁃617. DOI: 10.1016/j.immuni.2026. 01.010.
［61］	Tian J, Cao Y, Li Y, et al. A sympathetic⁃eosinophil axis orchestrates psychological stress to exacerbate skin inflammation［J］. Science, 2026,391（6791）:1269⁃1277. DOI: 10.1126/science. adv5974.
［62］	Noda S, Suárez⁃Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization［J］. J Allergy Clin Immunol, 2015,136（5）:1254⁃1264. DOI: 10.1016/j.jaci.2015. 08.015.
［63］	Wu Y, Gu C, Wang S, et al. Serum biomarker⁃based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab［J］. Br J Dermatol, 2023,188（5）:649⁃660. DOI: 10. 1093/bjd/ljad032.
［64］	Gu C, Wu Y, Luo Y, et al. Real⁃world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single⁃centre, prospective, open⁃label study［J］. J Eur Acad Dermatol Venereol, 2022,36（7）:1064⁃1073. DOI: 10.1111/jdv.18109.
［65］	Wang Y, Wu Y, Gu C, et al. Peripheral blood mononuclear cell⁃ transcriptome signatures of atopic dermatitis and prediction for the efficacy of dupilumab［J］. J Dermatol Sci, 2023,111（3）:83⁃92. DOI: 10.1016/j.jdermsci.2023.06.002.
［66］	Song X, Liu B, Luan T, et al. Moderate⁃to⁃severe atopic dermatitis in different age groups treated with dupilumab in China［J］. Allergy, 2023,78（6）:1696⁃1699. DOI: 10.1111/all. 15660.
［67］	Wang A, Zhou Y, Luo Y, et al. High loading⁃dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis［J］. Front Immunol, 2023,14:1160710. DOI: 10.3389/fimmu.2023.1160710.
［68］	Mao L, Yin H, Qiu Z, et al. Opsin 3 in keratinocytes mediates the light⁃induced exaggeration of atopic dermatitis［J］. J Allergy Clin Immunol, 2025,156（4）:980⁃992. DOI: 10.1016/j.jaci.2025. 05.015.
［69］	Tong Z, Zhang Y, Zhou K, et al. An observational study of abrocitinib in adults with moderate⁃to⁃severe atopic dermatitis after switching from dupilumab［J］. J Am Acad Dermatol, 2023,89（4）:826⁃828. DOI: 10.1016/j.jaad.2023.05.077.
［70］	Li Z, Wang Y, Wu Y, et al. Real⁃world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single⁃center prospective study［J］. Allergy, 2025,80（5）:1417⁃1427. DOI: 10.1111/all.16495.
［71］	Wang Y, Yin H, Li Z, et al. Blood transcriptome signature as indicator and predictor for efficacy of abrocitinib in treatment of atopic dermatitis［J］. J Invest Dermatol, 2025,145（10）:2524⁃2534. DOI: 10.1016/j.jid.2025.02.145.
［72］	Gao Y, Luo Y, Gao Y, et al. Baseline expression levels of WNT8B, KRT2, and TTLL13P are associated with abrocitinib response in atopic dermatitis［J］. JAAD Int, 2026,24:191⁃193. DOI: 10.1016/j.jdin.2025.10.007.
［73］	Huang D, Lu J, Tan F. Improvement of pruritus and efficacy in the early stage of therapy with upadacitinib, abrocitinib, or dupilumab in Chinese patients with moderate⁃to⁃severe atopic dermatitis: prospective, cohort, observational study［J］. Dermatitis, 2024,35（1）:77⁃83. DOI: 10.1089/derm.2023.0132.
［74］	Chen Y, Cao Q, Peng C, et al. Real⁃world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate⁃to⁃severe atopic dermatitis: a single⁃center, prospective study in China［J］. Front Med, 2024,18（4）:752⁃756. DOI: 10.1007/s11684⁃024⁃1063⁃9.
［75］	Zhao Y, Zhang L, Zhang J, et al. Efficacy and safety of stapokibart （CM310） in adults with moderate⁃to⁃severe atopic dermatitis: a multicenter, randomized, double⁃blind, placebo⁃controlled phase 3 trial［J］. J Am Acad Dermatol, 2024,91（5）:984⁃986. DOI: 10.1016/j.jaad.2024.07.1447.
［76］	Zhao Y, Gooderham M, Yang B, et al. Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2025,161（7）:688⁃697. DOI: 10.1001/jamadermatol.2025.0982.
［77］	Zhao Y, Wei Z, Feng Y, et al. Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: a phaseⅢ randomized clinical trial［J/OL］. Chin Med J （Engl）, 2025（2025⁃09⁃16）［2026⁃02⁃01］. https://journals.lww.com/cmj/fulltext/9900/efficacy_and_safety_of_benvitimod_1__ cream_for.1742.aspx. DOI: 10.1097/CM9.0000000000003769. ［published online ahead of print］.

[1]	田静宋志强. 胶带剥离法在特应性皮炎生物标志物检测中的研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 578-581.
[2]	中华医学会皮肤性病学分会儿童皮肤病学组中华医学会儿科学分会皮肤病学组中国康复医学会皮肤病康复专业委员会儿童学组中国康复医学会皮肤病康复专业委员会特应性皮炎学组中国医师协会皮肤科医师分会儿童皮肤病学组中国医师协会儿科学分会皮肤病学组. 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(6): 487-504.
[3]	杜欣冉王歆荷李思宇陈谟安袁少杰鄢然程淋燕郭婉军王怡李福伦. [开放获取] 特应性皮炎血虚风燥证诊断量表的构建及评价研究[J]. 中华皮肤科杂志, 2026, 59(6): 540-546.
[4]	许朋高玉文卢梦梁雄顺李雁冰洪文旭赵志广关杨. 槲皮素对DNFB诱导的特应性皮炎样小鼠肠道菌群稳态及炎症因子的影响及其与症状改善的关联分析[J]. 中华皮肤科杂志, 2026, 59(6): 529-539.
[5]	秦琬宜路永红唐欣韵周思婕周培媚. [开放获取] 度普利尤单抗/Janus激酶1抑制剂治疗中重度特应性皮炎的1年药物留存分析[J]. 中华皮肤科杂志, 2026, 59(6): 512-518.
[6]	张汉伊郭也也肖易陈翔粟娟. 慢性心理应激介导脂质代谢与免疫微环境异常在特应性皮炎样小鼠中的作用[J]. 中华皮肤科杂志, 2026, 59(6): 519-528.
[7]	伍博陈星柴圆圆曹蓉陈钱朱红艳. 不同严重程度儿童特应性皮炎血清维生素D水平与巨噬细胞炎症的相关性分析[J]. 中华皮肤科杂志, 2026, 59(6): 547-552.
[8]	李雁冰许朋田佳彬林秀球刘慧赵志广李祥子关杨. 成人特应性皮炎流行病学分析：基于2023年深圳市慢性病及危险因素监测数据[J]. 中华皮肤科杂志, 2026, 59(6): 553-557.
[9]	葛佳艺刘伊瑄周园姚煦. 特应性皮炎中移动健康与数字生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 571-577.
[10]	李明李妍李邻峰. Janus激酶抑制剂在中重度特应性皮炎中的应用进展[J]. 中华皮肤科杂志, 2026, 59(6): 582-585.
[11]	李芳林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 586-590.
[12]	马铜川邓婷月肖风丽. 吸烟与特应性皮炎相关性研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 590-593.
[13]	张笑旭罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2026, 59(5): 459-463.
[14]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤病学分会. [开放获取] 肠道菌群移植治疗银屑病专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 427-435.
[15]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会 . [开放获取] 老年银屑病诊疗与康复专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 407-418.

中国特应性皮炎的研究现状与展望

Research on atopic dermatitis in China: current status and future perspectives

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 77

相关文章 15

Metrics

本文评价

推荐阅读 10